The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
Open accessAbstract
HIV-1 entry into CD4+cells requires the sequential interactions of the viral envelope glycoproteins with CD4 and a coreceptor such as the chemokine receptors CCR5 and CXCR4. A plausible approach to blocking this process is to use small molecule antagonists of coreceptor function. One such inhibitor has been described for CCR5: the TAK-779 molecule. To facilitate the further development of entry inhibitors as antiviral drugs, we have explored how TAK-779 acts to prevent HIV-1 infection, and we have mapped its site of interaction with CCR5. We find that TAK-779 inhibits HIV-1 replication at the membrane fusion stage by blocking the interaction of the viral surface glycoprotein gp120 with CCR5. We could identify no amino acid substitutions within the extracellular domain of CCR5 that affected the antiviral action of TAK-779. However, alanine scanning mutagenesis of the transmembrane domains revealed that the binding site for TAK-779 on CCR5 is located near the extracellular surface of the receptor, within a cavity formed between transmembrane helices 1, 2, 3, and 7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., et al. (1996) · Nature · doi:10.1038/381667a0 · Cited by 3,174
Self-citationLiu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., & Landau, N. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80110-5 · Cited by 3,074
Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., & Lusso, P. (1995) · Science · doi:10.1126/science.270.5243.1811 · Cited by 2,869
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease
Berger, E. A., Murphy, P. M., & Farber, J. M. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.657 · Cited by 2,180
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119
Doranz, B. J., Rucker, J., Yi, Y., Smyth, R. J., Samson, M., Peiper, S. C., Parmentier, M., Collman, R. G., & Doms, R. W. (1996) · Cell · doi:10.1016/s0092-8674(00)81314-8 · Cited by 1,833
The antigenic structure of the HIV gp120 envelope glycoprotein
Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., Hendrickson, W. A., & Sodroski, J. G. (1998) · Nature · doi:10.1038/31514 · Cited by 1,203
Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998) · Nature Medicine · doi:10.1038/3293 · Cited by 987
Lucas, G. M., Chaisson, R. E., & Moore, R. D. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-2-199907200-00002 · Cited by 843
Cited by
González-Scarano, F., & Martín-García, J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1527 · Cited by 1,097
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
Chemokine:Receptor Structure, Interactions, and Antagonism
Allen, S. J., Crown, S. E., & Handel, T. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090529 · Cited by 839
Unraveling hot spots in binding interfaces: progress and challenges
DeLano, W. L. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00283-x · Cited by 767
Chemokine receptors: multifaceted therapeutic targets
Proudfoot, A. E. I. (2002) · Nature Reviews Immunology · doi:10.1038/nri722 · Cited by 752
Allosteric Modulation of G Protein–Coupled Receptors
May, L. T., Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105159 · Cited by 695
Strategies in the design of antiviral drugs
De Clercq, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd703 · Cited by 652
Kristiansen, K. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.05.002 · Cited by 609
Chemokines and Their Receptors: Drug Targets in Immunity and Inflammation
Viola, A., & Luster, A. D. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.121806.154841 · Cited by 583
Emerging paradigms in GPCR allostery: implications for drug discovery
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498
Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells
Yi, L., Li, Z., Yuan, K., Qu, X., Chen, J., Wang, G., Zhang, H., Luo, H., Zhu, L., Jiang, P., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.20.11334-11339.2004 · Cited by 485
HIV-1 Envelope Glycoprotein Biosynthesis, Trafficking, and Incorporation
Checkley, M. A., Luttge, B. G., & Freed, E. O. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.04.042 · Cited by 479
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Matthews, T., Salgo, M., Greenberg, M., Chung, J., DeMasi, R., & Bolognesi, D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1331 · Cited by 465
Mori, T., Doi, R., Koizumi, M., Toyoda, E., Ito, D., Kami, K., Masui, T., Fujimoto, K., Tamamura, H., Hiramatsu, K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.29.3.1 · Cited by 407
Chemokine receptor CCR5: insights into structure, function, and regulation
Oppermann, M. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.04.007 · Cited by 376
Lipid Rafts and HIV Pathogenesis: Host Membrane Cholesterol Is Required for Infection by HIV Type 1
Liao, Z., Cimakasky, L. M., Hampton, R., Nguyen, D. H., & Hildreth, J. E. K. (2001) · AIDS Research and Human Retroviruses · doi:10.1089/088922201300343690 · Cited by 355
Bertini, R., Allegretti, M., Bizzarri, C., Moriconi, A., Locati, M., Zampella, G., Cervellera, M. N., Di Cioccio, V., Cesta, M. C., Galliera, E., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402090101 · Cited by 333
Watson, C., Jenkinson, S., Kazmierski, W., & Kenakin, T. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008565 · Cited by 302
Strizki, J. M., Xu, S., Wagner, N. E., Wojcik, L., Liu, J., Hou, Y., Endres, M., Palani, A., Shapiro, S., Clader, J. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221375398 · Cited by 299
Self-citationResistance to enfuvirtide, the first HIV fusion inhibitor
Greenberg, M. L. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh330 · Cited by 258
Novel Therapies Based on Mechanisms of HIV-1 Cell Entry
Kilby, J. M., & Eron, J. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022812 · Cited by 254
Tilton, J. C., Wilen, C. B., Didigu, C. A., Sinha, R., Harrison, J. E., Agrawal-Gamse, C., Henning, E. A., Bushman, F. D., Martin, J. N., Deeks, S. G., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01109-10 · Cited by 110
Metadata
- Authors
- Dragic, T., Trkola, A., Thompson, D. A. D., Cormier, E. G., Kajumo, F. A., Maxwell, E., Lin, S. W., Ying, W., Smith, S. O., Sakmar, T. P., & Moore, J. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-04-25
- Volume
- 97
- Issue
- 10
- Pages
- 5639-5644
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2044004371
- Cited by
- 426
- References
- 46
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.